Macrophage migration inhibitory factor (MIF) is a potential therapeutic for HFD-induced insulin resistance and controlling its activities with pharmacological mediators or functional foods could be therapeutically viable for the treatment and prevention of obesity-related metabolic disorders and insulin resistance (13). This evidence concerns the gene MIF and obesity due to melanocortin 4 receptor deficiency.